Cinctive Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cinctive Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,278	Closed	-$7.17M	–	533
2026 Q1	$7.17M	Buy	9,278 +2,935	+46%	+$2.25M	0.47%	65
2025 Q4	$4.9M	Buy	6,343 +4,406	+227%	+$2.99M	0.27%	110
2025 Q3	$1.09M	Sell	1,937 -1,172	-38%	-$663K	0.05%	298
2025 Q2	$1.63M	Buy	+3,109	New	+$1.74M	0.09%	239
2024 Q4	–	Sell	-2,973	Closed	-$3.13M	–	462
2024 Q3	$3.13M	Sell	2,973 -6,711	-69%	-$7.47M	0.17%	185
2024 Q2	$10.2M	Buy	9,684 +797	+9%	+$773K	0.48%	54
2024 Q1	$8.55M	Buy	8,887 +2,887	+48%	+$2.75M	0.4%	68
2023 Q4	$5.27M	Buy	+6,000	New	+$4.94M	0.35%	101

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cinctive Capital Management's REGN Position: Q2 2026 in Review

Cinctive Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 9,278 shares — an estimated $7.17M sold.

Cinctive Capital Management first reported a position in REGN in Q4 2023 and held it in 8 quarters. The position peaked at $10.2M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Cinctive Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cinctive Capital Management sold 9,278 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.17M.
Cinctive Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Cinctive Capital Management's Regeneron Pharmaceuticals position peaked at $10.2M in Q2 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.